Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Impedimed Ltd

Healthcare AU IPD

0.007AUD
-0.001(12.50%)

Last update at 2026-06-04T06:10:00Z

Day Range

0.0070.008
LowHigh

52 Week Range

0.0060.06
LowHigh

Fundamentals

  • Previous Close 0.008
  • Market Cap12.23M
  • Volume1050889
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-22.16000M
  • Revenue TTM14.23M
  • Revenue Per Share TTM0.007
  • Gross Profit TTM 12.26M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -23.21100M -20.72500M -20.49000M -19.82800M -20.66700M
Minority interest - - - - -
Net income -23.23700M -19.79000M -20.52100M -19.87400M -20.70600M
Selling general administrative 21.51M 22.09M 19.51M 18.15M 21.42M
Selling and marketing expenses 0.80M 0.52M 0.46M 0.67M 0.45M
Gross profit 10.97M 9.01M 9.70M 8.79M 6.75M
Reconciled depreciation 4.56M 2.25M 2.50M 2.77M 1.70M
Ebit -22.11700M -24.30400M -22.99300M -21.53700M -23.07300M
Ebitda -17.55300M -22.05100M -20.49300M -18.76800M -21.37300M
Depreciation and amortization 4.56M 2.25M 2.50M 2.77M 1.70M
Non operating income net other - - - - -
Operating income -24.23100M -19.03600M -22.86500M -21.46600M -22.96700M
Other operating expenses 36.95M 29.36M 32.60M 30.41M 29.05M
Interest expense 1.09M 0.09M 0.77M 0.02M 2.41M
Tax provision 0.03M 0.03M 0.03M 0.05M 0.04M
Interest income 0.96M 1.56M 0.80M 0.05M 0.02M
Net interest income -0.20400M 1.47M 0.77M 0.02M -0.05200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M -0.93500M 0.03M 0.05M 0.04M
Total revenue 12.72M 10.32M 11.25M 10.49M 8.35M
Total operating expenses 35.21M 28.04M 32.70M 30.32M 29.82M
Cost of revenue 1.75M 1.31M 1.55M 1.71M 1.60M
Total other income expense net 1.02M -1.68900M 1.70M 1.69M 2.44M
Discontinued operations - - - - -
Net income from continuing ops -23.23700M -19.79000M -20.52100M -19.87400M -20.70600M
Net income applicable to common shares -23.23700M -19.79000M -20.52100M -19.87400M -20.70600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 41.66M 46.99M 68.74M 58.70M 34.20M
Intangible assets 10.19M 13.31M 12.04M 8.74M 5.04M
Earning assets - - - - -
Other current assets 0.69M 0.86M 0.54M 0.97M 0.90M
Total liab 21.16M 6.24M 7.86M 7.66M 8.69M
Total stockholder equity 20.50M 40.74M 60.88M 51.04M 25.51M
Deferred long term liab - - - - -
Other current liab 2.60M 1.73M 1.03M 0.93M 0.88M
Common stock - 336.15M 336.09M 307.56M 267.27M
Capital stock 336.15M 336.15M 336.09M 307.56M 267.27M
Retained earnings -354.18900M -330.95200M -311.16200M -290.64100M -270.76700M
Other liab - - 0.86M 0.41M 0.40M
Good will 2.78M 2.72M 2.73M 2.63M 2.42M
Other assets - - - 0.26M -
Cash 22.18M 24.63M 45.71M 40.73M 19.68M
Cash and equivalents - - 13.55M 31.29M 11.50M
Total current liabilities 5.66M 4.66M 5.85M 7.24M 8.13M
Current deferred revenue - 1.49M 3.16M 3.51M 5.65M
Net debt - -23.48900M -44.26300M -40.56000M -19.20700M
Short term debt - 0.33M 0.30M 0.17M 0.32M
Short long term debt - - - - -
Short long term debt total - 1.14M 1.45M 0.17M 0.47M
Other stockholder equity - - 8.05M 34.13M 29.01M
Property plant equipment - - 1.95M 0.42M 1.03M
Total current assets 27.51M 29.46M 51.94M 46.66M 25.65M
Long term investments 0.07M 0.05M 0.08M 0.07M 0.07M
Net tangible assets - - 46.11M 39.68M 18.06M
Short term investments - - - - -
Net receivables 1.93M 3.20M 3.84M 3.41M 3.71M
Long term debt 13.79M - - - -
Inventory 0.86M 0.76M 0.81M 0.93M 0.37M
Accounts payable 1.06M 1.10M 1.35M 2.64M 1.30M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 35.55M 35.95M 34.13M 29.01M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.23M 13.31M -16.80100M 0.18M -8.55500M
Deferred long term asset charges - - - - -
Non current assets total 14.15M 17.53M 16.80M 12.04M 8.55M
Capital lease obligations 0.70M 1.14M 1.45M 0.17M 0.47M
Long term debt total - - 1.15M 0.00000M 0.16M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.98900M -3.10500M -6.04300M -5.22100M -2.45700M
Change to liabilities - - -0.89400M 1.53M -0.28300M
Total cashflows from investing activities -0.98900M -3.10500M -6.04300M -5.22100M -2.45700M
Net borrowings 15.97M - -0.42500M -0.37300M -0.24000M
Total cash from financing activities 13.64M -0.48100M 27.93M 39.92M 16.47M
Change to operating activities - - 0.17M -2.79400M 2.65M
Net income -23.23700M -19.79000M -20.52100M -19.87400M -20.70600M
Change in cash -2.44900M -21.07800M 4.98M 21.05M 0.02M
Begin period cash flow 24.63M 45.71M 40.73M 19.68M 19.66M
End period cash flow 22.18M 24.63M 45.71M 40.73M 19.68M
Total cash from operating activities -14.64500M -17.78900M -18.04900M -15.66400M -13.25800M
Issuance of capital stock - 0.06M 30.02M 42.50M 16.84M
Depreciation - 2.25M 0.68M 1.24M 0.35M
Other cashflows from investing activities -0.92900M -3.02400M - - -
Dividends paid - - -0.42500M -0.37300M -0.58000M
Change to inventory - 0.05M 0.12M -0.55400M 0.49M
Change to account receivables - 1.18M 0.18M 0.04M -0.08400M
Sale purchase of stock 0.00000M -0.06200M -1.51600M -2.21300M -0.13300M
Other cashflows from financing activities -2.32500M -0.47700M 0.28M 0.37M 0.75M
Change to netincome - - 0.30M 2.95M 2.97M
Capital expenditures 0.99M 3.10M 6.04M 5.22M 2.46M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -18.88100M 0.41M 0.29M -0.51500M 0.41M
Stock based compensation - -0.68000M 0.75M 3.00M 3.04M
Other non cash items -14.64500M 0.02M 1.79M 2.97M 7.09M
Free cash flow -15.63400M -20.89400M -24.09200M -20.88500M -15.71500M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IPD
Impedimed Ltd		 -0.001 12.50% 0.007 - - 0.86 1.47 1.12 -9.3366
COH
Cochlear Ltd		 - -% 95.10 18.48 18.62 2.72 3.31 2.76 11.44
4DX
4DMEDICAL Ltd		 0.13 3.43% 3.92 - - 340.72 37.59 355.67 -7.2899
AVR
Anteris Technologies Global Corp		 -1.01 7.77% 11.99 - - 630.02 3.17 326.80 -5.1986
PNV
Polynovo Ltd		 -0.005 0.47% 1.07 125.50 40.49 6.22 10.01 5.96 119.61

Reports Covered

Stock Research & News

View All

Profile

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.

Impedimed Ltd

5900 Pasteur Court, Carlsbad, CA, United States, 92008

Key Executives

Name Title Year Born
Mr. Timothy Cruickshank Chief Financial Officer NA
Mr. Shashi Tripathi COO, CTO & Chief Customer Officer NA
Mr. Dennis Schlaht Sr. VP of R&D and Technology NA
Ms. Catherine Kingsford Sr. VP of Medical Affairs NA
Mr. David W. Anderson B.S. Exec. Director 1954
Mr. Richard P. Valencia MD & CEO 1962
Mr. Michael John Bassett Chief Commercial Officer, Sr. VP of Corp. & Strategic Devel. and GM of Renal NA
Ms. Nancy T. Deisinger Sr. VP of HR NA
Dr. Thomas Schenk Chief Medical Officer NA
Ms. Leanne Ralph AAICD, ACIS, BBus Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.